OTCMKTS:AMAR Amarillo Biosciences (AMAR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Amarillo Biosciences Stock (OTCMKTS:AMAR) Get Amarillo Biosciences alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume6,100 shsAverage Volume18,253 shsMarket Capitalization$25.24 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Amarillo Biosciences, Inc., a healthcare company, engages in the discovery and development of pharmaceutical and biotech products in the United States and Asia. The company operates in three divisions: Pharmaceutical, Medical, and Consumer. The Pharmaceutical division offers low-dose non-injectable interferon (IFN) for the treatment of neoplastic, viral, and fibrotic diseases. The Medical division focuses on medical devices and developing technology to treat metabolism related diseases, such as Type 1 and Type 2 diabetes. The Consumer division provides a range of nutraceutical and food supplement products that utilize a liposomal delivery system. It owns four issued patents related to the low-dose oral delivery of interferon; one patent is for a product promoting oral health; and three patents are associated with treatment of metabolic disorders. The company was incorporated in 1984 and is based in Amarillo, Texas. Read More Receive AMAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amarillo Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AMAR Stock News HeadlinesAmarillo native earns Rising Star awardJune 26, 2025 | msn.comAmarillo native, Navy veteran earns Rising Star Award for leadership in electric vehicle sectorJune 26, 2025 | msn.comMy feud with Zohran MamdaniNearly 40% of Americans now hold a positive view of socialism - and former hedge fund manager Whitney Tilson says what's unfolding in New York City is just the beginning. Tilson, a Harvard MBA who spent 30 years on Wall Street, has identified a specific economic pattern he believes points to a financial reset unlike anything seen in over 100 years. He's released a free analysis outlining what's coming and the exact steps he recommends you take with your money now. | Stansberry Research (Ad)Vikings Acquire RB Cam Akers in Midseason Trade With TexansOctober 17, 2024 | msn.comFrance’s divided National Assembly votes to keep centrist speaker as political turmoil persistsJuly 20, 2024 | msn.comAmarillo, United States - Weather Forecasts | Maps | News - Yahoo WeatherMay 7, 2024 | yahoo.comTexas Rising Stars award honors two Amarillo lawyersApril 2, 2024 | msn.comRising Stars attorneys, Midland wildfire donations among this week's business newsMarch 31, 2024 | msn.comSee More Headlines AMAR Stock Analysis - Frequently Asked Questions How were Amarillo Biosciences' earnings last quarter? Amarillo Biosciences, Inc. (OTCMKTS:AMAR) announced its quarterly earnings data on Wednesday, November, 14th. The company reported ($0.01) earnings per share (EPS) for the quarter. The business had revenue of $0.02 million for the quarter. How do I buy shares of Amarillo Biosciences? Shares of AMAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Amarillo Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amarillo Biosciences investors own include Fulcrum Therapeutics (FULC), Cerecor (CERC), AquaBounty Technologies (AQB), Astria Therapeutics (ATXS) and Company Calendar Last Earnings11/14/2018Today6/23/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolOTCMKTS:AMAR CIK1014763 Webwww.amarbio.com Phone806-376-1741FaxN/AEmployees2Year Founded1984Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.45 million Net Margins-41,453.98% Pretax MarginN/A Return on EquityN/A Return on Assets-574.29% Debt Debt-to-Equity RatioN/A Current Ratio0.03 Quick Ratio0.07 Sales & Book Value Annual Sales$20 thousand Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.03) per share Price / BookN/AMiscellaneous Outstanding Shares42,066,000Free FloatN/AMarket Cap$25.24 million OptionableNot Optionable Beta-0.06 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (OTCMKTS:AMAR) was last updated on 6/24/2026 by MarketBeat.com Staff. From Our PartnersYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredEvery time Musk needs a company, he buys itMusk needed batteries - he built the Gigafactory. Needed solar - acquired SolarCity. Needed data - bought Twit...Behind the Markets | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIt's time to "buy the dip" in goldGold just posted a significant correction - and one analyst calls it the biggest buy-the-dip opportunity of th...Golden Portfolio | SponsoredTop Banks Warn: A Strange Day is Coming to AmericaGoldman Sachs and Morgan Stanley are warning clients about a developing crisis that could suppress portfolio g...TradeSmith | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarillo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amarillo Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
